188 related articles for article (PubMed ID: 31201896)
1. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor.
Yoshida S; Takahara T; Arita Y; Ishii C; Uchida Y; Nakagawa K; Toda K; Sakamoto T; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Yoshimura R; Fujii Y
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):376-381. PubMed ID: 31201896
[TBL] [Abstract][Full Text] [Related]
2. Genuine- and induced-oligometastatic castration-resistant prostate cancer: clinical features and clinical outcomes after progressive site-directed therapy.
Yoshida S; Takahara T; Arita Y; Toda K; Yamada I; Tanaka H; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int Urol Nephrol; 2021 Jun; 53(6):1119-1125. PubMed ID: 33452956
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence in genuine and induced oligometastatic castration-resistant prostate cancer treated with progressive site-directed therapy.
Yoshida S; Takahara T; Arita Y; Toda K; Kimura K; Fujiwara M; Tanaka H; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Int J Urol; 2023 Feb; 30(2):204-210. PubMed ID: 36314128
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response.
Yoshida S; Takahara T; Arita Y; Toda K; Kimura K; Tanaka H; Yokoyama M; Matsuoka Y; Yoshimura R; Fujii Y
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158833
[TBL] [Abstract][Full Text] [Related]
6. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
[TBL] [Abstract][Full Text] [Related]
9. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer.
Deek MP; Taparra K; Phillips R; Velho PI; Gao RW; Deville C; Song DY; Greco S; Carducci M; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Tran PT; Stish BJ
Eur Urol Oncol; 2021 Jun; 4(3):447-455. PubMed ID: 32536574
[TBL] [Abstract][Full Text] [Related]
10. Progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
Lee JN; Kim MY; Kang JH; Kang JK; Chung JW; Ha YS; Choi SH; Kim BS; Kim HT; Kim TH; Yoo ES; Kim SH; Kwon TG
Investig Clin Urol; 2024 Mar; 65(2):132-138. PubMed ID: 38454822
[TBL] [Abstract][Full Text] [Related]
11. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
[TBL] [Abstract][Full Text] [Related]
12. [Availability of Local Therapy to Castration-Resistant Prostate Cancer for M0 Patients with Initial Prostate Specific Antigen 100 ng/ml or Higher].
Kuromoto A; Tanaka T; Koyama J; Goto T; Kimura S; Katsumata Y; Myoen S; Ozawa M; Morozumi K; Sato M; Hoshi S; Numahata K; Arai Y
Hinyokika Kiyo; 2017 Dec; 63(12):515-520. PubMed ID: 29370662
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
14. Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
Mori K; Kimura T; Ito K; Onuma H; Tanaka M; Matsuura T; Kurokawa G; Iwatani K; Inaba Y; Sakanaka K; Sasaki H; Miki J; Shimomura T; Miki K; Egawa S
Prostate; 2018 Jul; 78(10):766-772. PubMed ID: 29635810
[TBL] [Abstract][Full Text] [Related]
15. Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.
Lee J; Sato MM; Coel MN; Lee KH; Kwee SA
J Nucl Med; 2016 Jul; 57(7):1058-64. PubMed ID: 26912444
[TBL] [Abstract][Full Text] [Related]
16. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
17. [
Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S
Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180
[TBL] [Abstract][Full Text] [Related]
18. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.
Mizokami A; Izumi K; Konaka H; Kitagawa Y; Kadono Y; Narimoto K; Nohara T; Bahl AK; Namiki M
Asian J Androl; 2017; 19(2):143-148. PubMed ID: 27270339
[TBL] [Abstract][Full Text] [Related]
19. Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study.
Ji G; Song G; Huang C; He S; Zhou L
Medicine (Baltimore); 2017 Sep; 96(36):e7823. PubMed ID: 28885333
[TBL] [Abstract][Full Text] [Related]
20. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
